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Significance of this study
What is already known about this subject?
 ► Although previous studies have demonstrated that 
quitting smoking decreases the risk of all- cause 
mortality in patients with diabetes, the effect of 
smoking cessation after new- onset type 2 diabetes 
on all- cause and cause- specific mortality compared 
with current smoking has not been assessed.
 ► There is limited evidence on the association be-
tween smoking cessation and mortality stratified by 
body mass index and exercise.
What are the new findings?
 ► Smoking cessation after new- onset type 2 diabetes 
was significantly associated with reduced mortality 
risk compared with current smoking.
 ► Smoking cessation after new- onset type 2 diabetes 
was associated with a reduced risk of mortality from 
cancer compared with current smoking.
 ► Smoking cessation after new- onset type 2 diabetes 
in non- obese and exerciser groups was associated 
with reduced mortality risk compared with current 
smoking.
How might these results change the focus of 
research or clinical practice?
 ► This study may provide additional evidence for cli-
nicians for advising patients with type 2 diabetes to 
quit smoking.
AbStrAct
Introduction This study aimed to examine the association 
between smoking cessation after new- onset type 2 
diabetes and overall and cause- specific mortality risks 
among Korean men.
Research design and methods The Korean National 
Health Insurance Service- National Health Screening Cohort 
database was searched, and 13 377 Korean men aged ≥40 
years diagnosed with new- onset type 2 diabetes between 
2004 and 2007 were included and followed up until 
2013. We defined smoking status changes by comparing 
participants’ answers in the last survey before diagnosis 
to those in the first survey after diagnosis. We estimated 
the adjusted HR (AHR) and 95% CI for mortality risk using 
multivariable Cox proportional hazards regression models.
Results We identified 1014 all- cause mortality events 
(cancer, n=406 and cardiovascular disease (CVD), n=184) 
during an average follow- up duration of 7.2 years. After 
adjustment for all confounding factors, the reduced 
risk of all- cause mortality was more significant among 
short- term quitters (AHR 0.78; 95% CI 0.64 to 0.95), 
long- term quitters (AHR 0.68; 95% CI 0.54 to 0.85), and 
never smokers (AHR 0.66; 95% CI 0.56 to 0.78) compared 
with current smokers (p for trend <0.001). The lower 
risk of mortality from cancer was significant among the 
short- term quitters (AHR 0.60; 95% CI 0.44 to 0.83), 
long- term quitters (AHR 0.67; 95% CI 0.46 to 0.90), and 
never smokers (AHR 0.50; 95% CI 0.39 to 0.65) compared 
with current smokers (p for trend <0.001). There was no 
significant association between changes in smoking status 
and death from CVD. Smoking cessation after diagnosis 
in non- obese individuals (AHR 0.73; 95% CI 0.58 to 0.92) 
and exercisers (AHR 0.54; 95% CI 0.38 to 0.76) was 
significantly associated with reduced mortality risk than 
current smoking.
Conclusions Smoking cessation after new- onset type 2 
diabetes was associated with reduced mortality risk.
InTRoduCTIon
Individuals with type 2 diabetes are at a 
higher mortality risk than those without 
diabetes.1 Smoking is a leading cause of 
premature mortality in patients with diabetes 
and the general population.2 A previous study 
involving women with type 2 diabetes has 
shown that current smokers have an increased 
mortality risk compared with never smokers.3 
A meta- analysis has revealed that smoking 
amplifies the risk of mortality and cardio-
vascular events in patients with diabetes.4 
Another meta- analysis has also indicated that 
active smoking is associated with significantly 
increased risks of total mortality and cardio-
vascular events compared with never smoking 
patients with diabetes.5
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Figure 1 Flow chart of the study participants.
Although the negative health effects of smoking last 
long, smoking cessation appears to reduce the risk of 
adverse health outcomes on a long- term basis.6 7 However, 
the potential reduction in mortality risk by quitting 
smoking is not clear in patients with type 2 diabetes. A 
prior study has examined the effects of quitting smoking 
on mortality risk in patients with diabetes.8 Another 
study has assessed the association of quitting smoking 
and mortality in women with type 2 diabetes.3 A recent 
study has examined the effects of quitting smoking and 
body mass index (BMI) changes on all- cause mortality in 
patients with diabetes.9 However, the effects of smoking 
cessation after new- onset type 2 diabetes on overall and 
cause- specific mortality have not been investigated.
Smoking cessation is a major target for diabetes treat-
ment.10 However, many patients continue to smoke even 
after being diagnosed with diabetes mellitus,11 and the 
success rate of smoking cessation interventions among 
patients with diabetes is low (approximately 20%).12 
This study may provide additional evidence for the likely 
benefits of quitting smoking after the diagnosis of type 2 
diabetes.
We examined the potential benefits of smoking cessa-
tion after new- onset type 2 diabetes in terms of reducing 
the risk of all- cause mortality using nationwide retro-
spective cohort data. We also explored the association 
between smoking cessation and deaths from cancer and 
cardiovascular disease (CVD) because cancer and CVD 
are the major causes of worldwide deaths,13 for which 
smoking is an important risk factor.14 15 Further, we iden-
tified the relationship between smoking cessation and all- 
cause mortality stratified by BMI and exercise.
MaTeRIals and MeTHods
data and study sample
The study data were extracted from the Korean National 
Health Insurance Service (NHIS)- National Health 
Screening Cohort (HEALS) database between 2002 and 
2013.16 The Korean NHIS operates a mandatory health 
insurance system and covers approximately 97% of the 
Korean population. All subscribers aged 40–79 years 
are required to have a standardized biannual health 
screening (annual for manual workers). The NHIS- 
HEALS was extracted using a simple random sampling 
method to establish a representative sample and 
comprised 10% (514 866 individuals) of all health exam-
ination participants from 2002 to 2003 who were followed 
up until 2013. The NHIS- HEALS data include demo-
graphics and clinical information regarding diagnoses, 
treatments, and prescribed drugs for all visits (inpatient, 
outpatient, and pharmacy visits) to healthcare facilities 
by cohort subjects. The NHIS- HEALS data also include 
national health screening information, performed bien-
nially from 2002 to 2013, consisting of chest radiographic 
examinations, regular blood tests, a survey questionnaire 
on medical history, and physical examinations.
Among the 513 268 participants from the NHIS- HEALS 
between 2004 and 2007, we excluded study subjects with 
type 1 diabetes between 2002 and 2007 (n=43 179). We 
also excluded subjects without type 2 diabetes to solely 
recruit patients with type 2 diabetes as study participants 
between 2004 and 2007 (n=388 611). Type 2 diabetes 
was defined as the existence of any one of the following 
criteria: (1) fasting blood glucose level of ≥7 mmol/L 
(126 mg/dL); (2) physician’s diagnosis of type 2 diabetes 
(the International Classification of Diseases 10th Revi-
sion (ICD-10) code: E11–E14) more than twice within 6 
months; (3) treatment with an oral hyperglycemic medi-
cation or insulin (online supplementary table 1). We 
also excluded subjects with type 2 diabetes between 2002 
and 2003 to include only patients with new- onset type 2 
diabetes (n=40 887). Finally, we excluded subjects who 
had no screening data before and after the diagnosis of 
diabetes or had missing information on smoking status 
(n=18 687) and excluded women (n=8527) because there 
was a significantly low proportion of current women 
smokers at baseline (below 5%). Finally, 13 377 subjects 
with newly diagnosed type 2 diabetes were included 
(figure 1).
Measurement
The dependent variables in this study were all- cause and 
cause- specific mortality. The cohort database was linked 
to the death registration database of Statistics Korea, 
which included the causes and dates of mortality. The 
various causes of death were coded according to ICD-10. 
Cause- specific mortality was classified as deaths from 
cancer (ICD-10 C00–C99) and CVD (ICD-10 I00–I99) 
based on previous studies.1 17 The survival duration was 
measured in days, and all subjects were followed up until 
mortality, withdrawal from the medical security system, or 
the end of 2013, whichever occurred first. The percentage 
of cases in which the status was not available at the end of 
the follow- up was approximately 0.5%.
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We used the smoking status assessed from the self- 
reported questionnaire surveyed in the national health 
screening as the independent variable. The question-
naire items regarding the smoking status included 
non- smoking, ex- smoking, and current smoking. We 
compared the participants’ answers on the smoking status 
in the latest survey before the diagnosis of diabetes with 
those in the first survey conducted after the diagnosis; the 
study subjects were divided into four groups based on the 
changes in their smoking status—current smoker, short- 
term quitter, long- term quitter, and never smoker. The 
study participants were classified as current smokers if 
they answered current smoking after diagnosis regardless 
of smoking status before diagnosis (n=3857); short- term 
quitters if they answered: (1) current smoking before 
diagnosis and non- smoking after diagnosis (n=942), (2) 
current smoking before diagnosis and ex- smoking after 
diagnosis (n=489), or (3) non- smoking before diag-
nosis and ex- smoking after diagnosis (n=768); long- term 
quitters if they answered: (1) ex- smoking both before 
and after diagnosis (n=859) or (2) ex- smoking before 
diagnosis and non- smoking after diagnosis (n=1037); 
and never smokers if they answered non- smoking both 
before and after diagnosis (n=4673). The surveyed date 
of smoking status after the diagnosis was defined as index 
date (start date of follow- up) in our study.
The potential confounding factors considered in anal-
yses available for adjustment were age, residential area, 
household income, BMI, systolic and diastolic blood pres-
sures (BP), fasting blood glucose level, total cholesterol 
level, family history of diabetes, heavy drinking, exercise, 
and comorbidities. All potential confounding factors, 
except comorbidities, were measured at the index date.
Household income was classified as low (<40th percen-
tile), middle (41st–80th percentiles), or high (81st–100th 
percentiles). Residential area was classified as metropol-
itan (capital), urban (local government where >1 million 
individuals live), or rural (other). The WHO recommen-
dations for Asian populations were used to categorize the 
individuals into five BMI groups: <18.5 kg/m2 (under-
weight), 18.5–22.9 kg/m2 (normal), 23.0–24.9 kg/m2 
(overweight), 25.0–29.9 kg/m2 (class I obese), or ≥30 kg/
m2 (class II obese).18 Individuals who consumed ≥30 g/
day of alcohol were defined as heavy drinkers,19 those 
who drank alcohol but not heavily were defined as non- 
heavy drinkers, and those who did not drink alcohol 
were defined as non- drinkers. Exercise was defined as 
performance of exercise at least once a week. Systolic 
and diastolic BPs were measured with subjects seated and 
after at least 5 min of rest. Blood samples were obtained 
after overnight fasting to measure the serum glucose, 
total cholesterol, and creatinine levels.
The comorbidities consisted of hypertension (ICD-10: 
I10–I15), renal failure (ICD-10: N17–N19), stroke (ICD-
10: I60–I63), ischemic heart disease (ICD-10: I20–I25), 
and cancer (ICD-10: C00–C99) and were assessed by 
screening information for physician’s diagnoses of study 
subjects before index date.
statistical analyses
The clinical and demographic characteristics of the study 
participants were compared based on the change in their 
smoking status using analysis of variance for continuous 
variables and Pearson’s χ2 test for categorical variables. 
Data were presented as mean±SD for continuous variables 
and as numbers (percentages) for categorical variables. 
For each participant, mortality was measured from the 
index date to 31 December 2013. The number of person- 
years of follow- up was counted and age- standardized 
mortality rates were estimated from changes in smoking 
status (online supplementary table 2).
Cox proportional hazards regression models were 
used to evaluate the association between smoking cessa-
tion and mortality, and adjusted HR (AHR) and 95% CI 
were calculated using the potential confounding factors 
described in table 1. The functional form of continuous 
variables (age, systolic BP, diastolic BP, fasting glucose 
level, and total cholesterol level) was assessed and the 
models were stratified by non- proportional covariates 
(systolic BP, diastolic BP, and total cholesterol level) 
(online supplementary figure 1). First, we analyzed 
the effect of smoking cessation after new- onset type 2 
diabetes on all- cause mortality. Second, we identified 
the association between smoking cessation and mortality 
from cancer and CVD. Finally, we examined the relation-
ship between smoking cessation and mortality stratified 
by BMI and exercise.
All data extraction and statistical analyses were 
performed using Statistical Analysis System (SAS) V.9.4 
(SAS Institute). Proportional hazards assumptions were 
evaluated statistically and satisfied for all models.
ResulTs
Our study enrolled 13 377 individuals aged ≥40 years with 
incident type 2 diabetes. We identified 1014 events of all- 
cause mortality (cancer, n=406 and CVD, n=184) during 
an average follow- up duration of 7.2±1.4 years. Table 1 
presents the general characteristics of study subjects 
based on changes in the smoking status. The proportions 
of subjects with obesity, high household income, and 
comorbidities were higher among short- term quitters 
than among current smokers. In contrast, the propor-
tions of subjects living in urban residential areas, with a 
family history of diabetes, who drank heavily, and who 
exercised were lower among the short- term quitters than 
among current smokers.
Figure 2 presents the AHRs and 95% CIs for the risk 
of overall and cause- specific mortality based on changes 
in smoking status (online supplementary table 2). After 
adjustment for all confounding factors, the reduced risk 
of all- cause mortality was more significant among short- 
term quitters (AHR 0.78; 95% CI 0.64 to 0.95), long- term 
quitters (AHR 0.68; 95% CI 0.54 to 0.85), and never 
smokers (AHR 0.66; 95% CI 0.56 to 0.78) compared 
with current smokers (p for trend <0.001). The lower 
risk of mortality from cancer was significant among the 
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Table 1 General characteristics of study subjects according to change of smoking status
Variables Total








n % n % n % n %
Total 13 377 4609 34.5 2199 16.4 1896 14.2 4673 34.9
Age (years) 56.4±9.1 54.4 8.5 57.0 9.0 56.6 9.3 58.1 9.3 <0.001
BMI (kg/m2) <0.001
  ≤18.5 244 130 2.8 24 1.1 24 1.3 66 1.4
  18.5–23 3842 1523 33.0 588 26.7 464 24.5 1267 27.1
  23–25 3781 1263 27.4 611 27.8 558 29.4 1349 28.9
  25–30 5085 1548 33.6 906 41.2 783 41.3 1848 39.5
  ≥30 425 145 3.1 70 3.2 67 3.5 143 3.1
BP (mm Hg)
  Systolic 130.1±16.1 129.1 16.0 130.0 16.1 130.4 15.3 131.0 16.5 <0.001
  Diastolic 81.2±10.5 80.8 10.5 81.0 10.6 81.5 10.2 81.4 10.6 0.016
Fasting glucose (mg/dL) 111.0±33.6 111.2 35.3 111.7 38.1 110.7 29.4 110.6 31.2 0.544
Total cholesterol (mg/dL) 196.3±37.5 197.4 37.6 197.2 38.3 197.0 36.4 194.6 37.5 0.001
Family history of diabetes 1014 372 8.1 158 7.2 168 8.9 316 6.8 0.014
Heavy drinking 1121 588 12.8 164 7.5 136 7.2 233 5.0 <0.001
Exercise 7547 2574 55.8 1157 52.6 1198 63.2 2618 56.0 <0.001
Household income <0.001
  Low 3598 1354 29.4 572 26.0 399 21.0 1273 27.2
  Middle 5173 1883 40.9 856 38.9 699 36.9 1735 37.1
  High 4606 1372 29.8 771 35.1 798 42.1 1665 35.6
Residential area <0.001
  Metropolitan 2068 619 13.4 362 16.5 320 16.9 767 16.4
  Urban 3963 1481 32.1 596 27.1 541 28.5 1345 28.8
  Rural 7346 2509 54.4 1241 56.4 1035 54.6 2561 54.8
Comorbidities
  Hypertension 6032 1720 37.3 1038 47.2 915 48.3 2359 50.5 <0.001
  Renal failure 198 46 1.0 40 1.8 32 1.7 80 1.7 0.010
  Stroke 636 158 3.4 104 4.7 107 5.6 267 5.7 <0.001
  Ischemic heart disease 2019 561 12.2 352 16.0 335 17.7 771 16.5 <0.001
  Cancer 1060 284 6.2 200 9.1 162 8.5 414 8.9 <0.001
Values are presented as mean±SD or n (%).
BMI, body mass index; BP, blood pressure.
short- term quitters (AHR 0.60; 95% CI 0.44 to 0.83), 
long- term quitters (AHR 0.67; 95% CI 0.46 to 0.90), and 
never smokers (AHR 0.50; 95% CI 0.39 to 0.65) compared 
with current smokers (p for trend <0.001). There was no 
significant association between changes in smoking status 
and death from CVD.
Figure 3 shows the AHRs and 95% CIs for the risk of 
all- cause mortality for individuals with different smoking 
behaviors stratified by BMI and exercise (online supple-
mentary table 3). In the non- obese (individuals with BMI 
<25 kg/m2) and exerciser groups, reduced risk of mortality 
was significant among short- term quitters (AHR 0.73, 0.54; 
95% CI 0.58 to 0.92, 95% CI 0.38 to 0.76, respectively), 
long- term quitters (AHR 0.67, 0.58; 95% CI 0.52 to 0.87, 
95% CI 0.42 to 0.80, respectively), and never smokers 
(AHR 0.64, 0.58; 95% CI 0.53 to 0.78, 95% CI 0.45 to 0.75, 
respectively) compared with current smokers. Lower risk 
of mortality was observed among long- term quitters in 
obese group (individuals with BMI >25 kg/m2) (AHR 0.61; 
95% CI 0.40 to 0.93) and never smokers in the obese (AHR 
0.61; 95% CI 0.44 to 0.84) and exerciser groups (AHR 
0.72; 95% CI 0.58 to 0.90) compared with current smokers.
dIsCussIon
This study had three main findings. First, smoking cessa-
tion after new- onset type 2 diabetes was associated with 
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Figure 3 Change of smoking status and risk of mortality as stratified by BMI and exercise. AHR, adjusted HR; BMI, body 
mass index.
Figure 2 Risk of overall and cause- specific mortality based on change of smoking status. AHR, adjusted HR; CVD, 
cardiovascular disease.
reduced risk of all- cause mortality compared with current 
smoking. Second, smoking cessation after new- onset type 
2 diabetes was significantly associated with a lower risk of 
mortality from cancer compared with current smoking. 
Third, smoking cessation after new- onset type 2 diabetes 
in the non- obese and exerciser groups was associated with 
a lower risk of mortality compared with current smoking.
The findings of previous studies regarding the effect 
of smoking status on mortality have been unclear.3 8 9 In 
a study by Chaturvedi et al, the all- cause mortality risks 
were higher for quitters than for never smokers.8 In the 
study by Al- Delaimy et al, women with type 2 diabetes who 
had stopped smoking for ≥10 years had lower mortality 
risk than never smokers3; however, they used the never 
smoking group as a reference group and it is difficult to 
identify the benefits of smoking cessation over current 
smoking. Cho et al investigated the association between 
smoking cessation by BMI changes and mortality and 
used non- reducers who did not reduce their smoking 
amount among current smokers as a reference group.9 
However, they did not observe any benefits of smoking 
cessation on mortality. Our study suggests benefits of 
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smoking cessation on mortality. Smoking cessation is 
particularly important for patients with type 2 diabetes 
because their risk of developing other morbidities is 
substantially augmented by smoking and insulin resis-
tance.20 In our study, smoking cessation after the diag-
nosis of type 2 diabetes was significantly associated with a 
reduced risk of all- cause mortality compared with current 
smoking. This indicates that quitting smoking may have 
health benefits after the diagnosis of type 2 diabetes.
We found that smoking cessation after new- onset type 
2 diabetes is significantly associated with a lower risk of 
mortality from cancer compared with current smoking, 
which is consistent with previous reports. In a study by 
Ohnishi et al,21 current smokers with type 2 diabetes 
had a higher risk of cancer mortality.21 Type 2 diabetes 
in itself is associated with cancer mortality.22 23 Hyper-
insulinemia accompanied by insulin resistance, chronic 
inflammation, and hyperglycemia are known mecha-
nisms of oncogenesis. Another reason for the association 
of type 2 diabetes with cancer is that patients with type 2 
diabetes are likely to have common cancer risk factors, 
such as smoking, obesity, and alcohol drinking. Ciga-
rette smoking is a strong risk factor for various types of 
cancer,24 and therefore, smoking cessation is encouraged 
among patients with type 2 diabetes.
One of the main findings of this study is that smoking 
cessation after new- onset type 2 diabetes in non- obese 
and exerciser groups was associated with a reduced risk 
of mortality compared with current smoking. However, in 
the obese and non- exerciser groups, there were no asso-
ciations between short- term smoking cessation after diag-
nosis of type 2 diabetes and mortality. Obesity or physical 
inactivity appears to counteract the survival benefits of 
smoking cessation.25 26 Hence, the evidence suggests that 
the benefits of smoking cessation may only be valid for 
relatively healthier patients with type 2 diabetes.
This study had several limitations. First, the smoking 
status was assessed on the basis of patients’ self- reported 
information without biochemical verification, which led 
to underestimation or overestimation of smoking cessa-
tion. We also could not determine the exact time of 
smoking cessation in the study subjects because of limited 
data availability. Further research is warranted to explore 
this association using data on the exact time of smoking 
cessation and biomarker test findings, such as urine 
cotinine levels. Second, although we attempted to adjust 
for diverse confounding variables using multivariate 
analyses, the possibility of residual confounding factors 
cannot be completely excluded. Third, the participation 
level in Korean national health screening was approxi-
mately 60% in 2007, and therefore, there may have been 
possible selection bias. Fourth, there may be possibili-
ties for misdiagnosis of type 2 diabetes. Although type 2 
diabetes can be diagnosed using HbA1c or oral glucose 
tolerance test in addition to the fasting blood glucose test, 
the information for the former two was not included in 
NHIS- HEALS data. The fasting blood glucose test results 
were based on a single measurement; however, the test 
usually needs to be repeated on a second day to diag-
nose diabetes. Furthermore, patients with type 3 diabetes 
may have been included as study subjects; we could not 
exclude them. Finally, our study included only a Korean 
population, and thus, the findings cannot be generalized 
to other ethnicities.
The strengths of our study include its longitudinal 
design and availability of abundant demographic, life-
style variable, comorbidity, and biomedical data. To our 
knowledge, this is the first study to examine the impact of 
smoking cessation after new- onset type 2 diabetes on the 
risk of mortality.
In conclusion, this cohort study of a Korean population 
demonstrated that smoking cessation after new- onset 
type 2 diabetes was associated with reduced risk of all- 
cause mortality. Although smoking cessation seems to be 
more effective before the diagnosis of diabetes, quitting 
smoking after the diagnosis of diabetes has health bene-
fits. We suggest that clinicians should encourage smokers 
with type 2 diabetes to quit smoking.
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